Literature DB >> 20952661

Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling.

Claudio Ceconi1, Laura Comini, Silvia Suffredini, Francesca Stillitano, Muriel Bouly, Elisabetta Cerbai, Alessandro Mugelli, Roberto Ferrari.   

Abstract

The aim of this study was to investigate the effect of chronic heart rate (HR) reduction with the hyperpolarization-activated current inhibitor ivabradine on the global phenotype of left ventricular (LV) remodeling in a ligated rat model. Seven days after coronary artery ligation, Wistar rats received ivabradine (10 mg · kg(-1) · day(-1) administered in drinking water) [myocardial infarction + ivabradine (MI+IVA), n = 22] or vehicle only (drinking water) (MI, n = 20) for 90 days. A sham group (n = 20) was included for model validation. MI+IVA rats had 12% lower HR (P < 0.01), improved LV volumes, 15% higher LV ejection fraction (LVEF, P < 0.01) than MI rats, and 33% reductions in both plasma atrial natriuretic peptide (ANP, P = 0.052) and cardiac hydroxyproline. Using patch-clamp, action potential duration was reduced and transient outward current density increased (P < 0.05). Cardiac energy metabolism was also improved (+33% creatine phosphate, P < 0.001; +15% ATP; and +9% energy charge, P < 0.05). Significant correlations were found between HR and parameters of cardiac metabolism, ANP, and LVEF (all P < 0.05). The HR-reducing properties of ivabradine prevent changes in the global phenotype of LV remodeling in the rat, optimize energy consumption, and avoid electrophysiological and structural remodeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952661     DOI: 10.1152/ajpheart.01117.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  19 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.

Authors:  S Suffredini; F Stillitano; L Comini; M Bouly; S Brogioni; C Ceconi; R Ferrari; A Mugelli; E Cerbai
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Acipimox-enhanced ¹⁸F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model.

Authors:  Mélanie Bousquenaud; Fatiha Maskali; Sylvain Poussier; Pierre-Yves Marie; Henri Boutley; Gilles Karcher; Daniel R Wagner; Yvan Devaux
Journal:  Int J Cardiovasc Imaging       Date:  2011-11-25       Impact factor: 2.357

4.  Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat.

Authors:  Bo Hyun Kim; Kyoung Im Cho; Seong Man Kim; Nari Kim; Jin Han; Jee Yeon Kim; In Ju Kim
Journal:  Heart Vessels       Date:  2012-11-11       Impact factor: 2.037

Review 5.  Heart rate reduction in heart failure: ivabradine or beta blockers?

Authors:  Maya Guglin
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

6.  Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue.

Authors:  Martina Del Lungo; Michele Melchiorre; Luca Guandalini; Laura Sartiani; Alessandro Mugelli; Istvan Koncz; Tamas Szel; Andras Varro; Maria Novella Romanelli; Elisabetta Cerbai
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 7.  Heart rate reduction in coronary artery disease and heart failure.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

8.  Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.

Authors:  Michael Böhm; Jeffrey Borer; Ian Ford; Jose R Gonzalez-Juanatey; Michel Komajda; Jose Lopez-Sendon; Jan-Christian Reil; Karl Swedberg; Luigi Tavazzi
Journal:  Clin Res Cardiol       Date:  2012-05-11       Impact factor: 5.460

9.  Hyperpolarization-activated cyclic nucleotide-gated channels and ventricular arrhythmias in heart failure: a novel target for therapy?

Authors:  Priyanthi Dias; Cesare M Terracciano
Journal:  J Am Heart Assoc       Date:  2013-06-07       Impact factor: 5.501

10.  Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Authors:  Jean-Claude Tardif; Eileen O'Meara; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Luigi Tavazzi; Karl Swedberg
Journal:  Eur Heart J       Date:  2011-08-29       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.